Problématique : La fibrillation auriculaire (FA) est la forme d'arythmie cardiaque la plus fréquente. La maladie du cœur droit (MCD) fait partie des facteurs de risque de la FA. L’inflammation, impliquant l’axe NLRP3-IL18-IL1β-IL6, affecterait les fibroblastes (FB) atriaux et jouerait un rôle important dans l’induction de FA. Peu d’études ont évalué le rôle de l’interleukine-(IL)-37, un inhibiteur de la voie IL18, dans la prévention de l’inflammation et la FA dans la MCD. Hypothèse: L’IL37 inhibe l’activation de l'inflammation et prévient le développement du substrat de la FA dans les FB auriculaires de rats MCD. Méthodes: La MCD a été induite chez des rats Wistar en réalisant une ligature du tronc pulmonaire (LTP), et des animaux témoins ont reçu une chirurgie factice (SHAM). Les FB atriaux ont été isolés et cultivés dans 5 conditions de traitement: Milieu normal, Supplémentation pro-inflammatoire [IL-6], Supplémentation anti-inflammatoire [IL-37], Inhibition de voies inflammatoires avec le Tocilizumab [anti-IL6R], Inhibition de voies anti-inflammatoires avec [anti-IL37]. La prolifération et la migration des FB furent évaluées par immunomarquage de (α-SMA). Les niveaux d'expression des molécules liées à la fibrose, les marqueurs inflammatoires et les marqueurs anti-inflammatoires ont été évalués par qPCR (gènes) et western blot (protéines). Résultats: Trois semaines après la chirurgie, les animaux LTP ont développé de l’hypertrophie et de la dilatation cardiaque associées à de l’inflammation et de la fibrose atriale droite. Comparés aux SHAM, les FB de rats MCD ont exprimé plus de marqueurs d’inflammation et de fibrose et cette surexpression a été exacerbée en présence d’IL-6, et normalisée en présence d’IL-37. Conclusion: Au niveau des FB isolés, un traitement à l’IL37 semble être une stratégie efficace pour prévenir l'inflammation et la fibrose atriale associées à la MCD. / Introduction: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. Right heart disease (RHD) is one of the risk factors for AF. Inflammation, involving the NLRP3-IL18-IL1β-IL6 axis affects atrial fibroblasts (FB) and play an important role in AF induction. Few studies have assessed the role of interleukin-(IL)-37, an IL18 pathway inhibitor, in preventing inflammation and AF in RHD. Hypothesis: IL37 inhibits the activation of inflammation and prevents AF substrate development in atrial FB of RHD rats. Methods: RHD was induced in Wistar rats by performing pulmonary artery banding (PAB) and control animals received SHAM surgery. Atrial FBs were isolated and cultured under 5 treatment conditions: Normal medium, Pro-inflammatory supplementation [IL-6], Anti-inflammatory supplementation [IL-37], Inhibition of inflammatory pathways with tocilizumab [anti-IL6R], Inhibition of anti-inflammatory pathways with [anti-IL37]. The proliferation and migration of FB were determined with scratch wound healing assay. The expression levels of fibrosis-related molecules, inflammatory markers and anti-inflammatory markers were assessed by qPCR (genes) and western blot (proteins). Results: Three weeks post-surgery, PAB animals developed right heart enlargement and dilation associated with inflammation and right atrial fibrosis. Compared to SHAM, FB from PAB rats expressed more markers of inflammation and fibrosis, and this overexpression was exacerbated in the presence of IL-6 and normalized in the presence of IL-37. Conclusion: At the level of isolated FB, treatment with IL37 seems to be an effective strategy to prevent atrial inflammation and fibrosis associated with RHD.

Implementation and uptake of novel and cost-effective medicines can improve patient health outcomes and healthcare efficiency. However, the relative uptake of new medicines recommended by the National Institute for Health and Care Excellence often lags behind other comparative countries’ health systems. One example is the uptake of direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation, which was slow and had a high level of unexplained variation across different health economies in England. This research aimed to explore barriers and enablers to the uptake of DOACs from the perspectives of patients, healthcare professionals, and key stakeholders by conducting systematic and narrative reviews and semi-structured interviews. Data collected from 21 patients, 23 healthcare professionals, and 23 key stakeholders recruited from three different health economies was analysed using the Framework method. The findings identified a range of intersecting factors acting as barriers and/or enablers to the uptake DOACs. While there were a wide range of experiences and views, an agreement between patients and healthcare professionals/key stakeholders on several identified factors was observed. Attributes of the innovation, characteristics of patients and prescribers, local health economy readiness for change, implementation process, and external health system context were suggested as influences. Mapping of the findings to the Diffusion of Innovations in Service Organisations model identified 11 components for a future toolkit development to facilitate uptake of nationally recommended new medicines. This thesis highlighted the role of patients, consideration of all costs associated with new medicines, and compatibility with the health economy’s care model impact on the uptake.

BACKGROUND:Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease. However, these agents have a slow onset of action which requires bridging therapy with heparin and its analogues, which are available only in parenteral route. To overcome these limitations, new oral anticoagulants such as factor Xa inhibitors and direct thrombin inhibitors have been developed. The aim of this article is to systematically review the phase 3 clinical trials of new oral anticoagulants in common medical conditions.METHODS:We searched PubMed (Medline) from January 2007 to February 2013 using "Oral anticoagulants", "New oral anticoagulants", "Randomized controlled trial", "Novel anticoagulants", "Apixaban", "Rivaroxaban", "Edoxaban", "Dabigatran etexilate", "Dabigatran" and a combination of the above terms. The available evidence from the phase 3 RCTs was summarized on the basis of individual drug and the medical conditions categorized into "atrial fibrillation", "acute coronary syndrome", "orthopedic surgery", "venous thromboembolism" and "medically ill patients".RESULTS:Apixaban, rivaroxaban and dabigatran have been found to be either non-inferior or superior to enoxaparin in prophylaxis of venous thromboembolism in knee and hip replacement with similar bleeding risk, superior to warfarin for stroke prevention in atrial fibrillation with significant reduction in the risk of major bleeding, non-inferior to aspirin for reducing cardiovascular death and stroke in acute coronary syndrome with significant increase in the risk of major bleed. Rivaroxaban and dabigatran are also superior to the conventional agents in the management of symptomatic venous thromboembolism. However, compared to enoxaparin, apixaban and rivaroxaban use lead to significantly increased bleeding risk in medically ill patients. Additional studies evaluating the specific reversal agents of these new drugs for the management of life-threatening bleeding or other adverse effects are necessary.CONCLUSION:Considering their pharmacological properties, their efficacy and bleeding complications, the new oral agents offer a net favourable clinical profile in orthopedic surgery, atrial fibrillation, acute coronary syndrome and increase the risk of bleeding in critically ill patients. Further studies are necessary to determine the long term safety and to identify the specific reversal agents of these new drugs.

Einleitung: Die zirkumferentielle Pulmonalvenenablation (CPVA) hat sich in den letzten Jahren als effektive Therapie bei Vorhofflimmern etabliert. Die Initiierung eines CPVA-Programms bleibt jedoch aufgrund der Komplexität der Prozedur und des Risikos lebensgefährlicher Komplikationen eine Herausforderung. Das Ziel dieser prospektiven Studie war es, die Effizienz und Sicherheit eines neuetablierten CPVA-Programms an einem medizinischen Zentrum mit zuvor wenig erfahrenen Untersuchern zu evaluieren.  Methoden und Ergebnisse: Zwischen 2006 und 2011 wurden 331 Patienten mit paroxysmalem und persistierendem Vorhofflimmern konsekutiv der zirkumferentiellen Pulmonalvenenablation zugeführt und unterzogen sich insgesamt 500 Prozeduren. Das mittlere Follow-Up betrug 648 ± 315 Tage. Die zunehmende Ablationspraxis führte neben der Prozessoptimierung zu einer deutlichen Reduzierung schwerwiegender Komplikationen. Prozedurdauer und Komplikationsrate erreichten nach 100 Ablationen ein stabiles und im Lichte der internationalen Literatur adäquates Niveau. Die Inzidenz schwerwiegender Komplikationen verringerte sich auf 1,3 - 1,9%. Insgesamt betrug der Anteil schwerwiegender Komplikationen 4%. Der Tod trat nicht auf. Keine der aufgetretenen Komplikationen führte zu einer permanenten Gesundheitsbeeinträchtigung der Patienten. Die Erfolgsraten waren seit Beginn des Programms auf einem konstanten Niveau und vergleichbar mit in der Literatur beschriebenen Werten.  Schlussfolgerung: Die vorliegende Studie zeigt, dass es gelingt, ein CPVA-Programm mit zuvor wenig erfahrenen Untersuchern effizient zu etablieren. Die Daten zeigen jedoch auch, dass mit einer erhöhten Komplikationsrate in der frühen Etablierungsphase zu rechnen ist. Nach 1,6 ± 0,7 Ablationen und einer Nachbeobachtung von einem Jahr waren 81,3% (266 / 327) der Patienten frei von symptomatischem Vorhofflimmern. Die Reablation ist eine wichtige Maßnahme, um die Erfolgsrate nachhaltig zu verbessern. Die Studie identifizierte Frührezidive innerhalb der Blanking-Periode und einen vergrößerten linken Vorhof als unabhängige Prädiktoren für die Rekurrenz von symptomatischem Vorhofflimmern.  Vor dem Hintergrund des steigenden Bedarfs an effektiven Therapien zur Behandlung von Vorhofflimmern sind die Ergebnisse dieser Studie hilfreich, um weitere CPVA-Programme zu planen und zu etablieren.

Cardiac arrhythmias are caused by a disruption of the normal initiation or propagation of electrical impulses in the heart. Hundreds of mutations in genes encoding ion channels or ion channel regulatory proteins are linked to congenital arrhythmia syndromes that increase the risk for sudden cardiac death. This dissertation focuses on how mutations in a gene (KCNQ1) that encodes a voltage-gated K+ ion channel (Kv7.1) can disrupt proper channel function and lead to abnormal repolarization of atrial and ventricular cardiomyocytes. In the heart, Kv7.1 coassembles with a regulatory protein to conduct the slowly activating delayed rectifier K+ current (IKs). Loss-of-function KCNQ1 mutations are linked to type 1 long QT syndrome (LQT1), and typically decrease IKs, which can lead to ventricular action potential (AP) prolongation. In patients, LQT1 is often characterized by an abnormally long corrected QT (QTc) interval on an electrocardiogram (ECG), and increases the risk for polymorphic ventricular tachycardias. KCNQ1 mutations are also linked to atrial fibrillation (AF), but cause a gain-of-function phenotype that increases IKs. Surprisingly, patients diagnosed with both LQT1 and AF are increasingly identified as genotype positive for a KCNQ1 mutation. The first aim of this dissertation was to determine a unique functional phenotype of KCNQ1 mutations linked to both arrhythmia syndromes by functional analyses via the whole-cell patch clamp technique in HEK293 cells. A proportion of patients with LQT1-linked KCNQ1 mutations do not have abnormal QTc prolongation known as latent LQT1. Interestingly, exercise can reveal abnormal QTc prolongation in these patients. During exercise, beta-adrenergic activation stimulates PKA to phosphorylate Kv7.1, causing an increase in IKs to prevent ventricular AP prolongation. Therefore, the second aim of this dissertation was to determine a molecular mechanism of latent LQT1 through functional analyses in HEK293 cells while incorporating pharmacological and phosphomimetic approaches to study PKA regulation of mutant Kv7.1 channels. The findings in this dissertation provide new insight into how KCNQ1 mutations disrupt the function of Kv7.1 in a basal condition or during beta-adrenergic activation. Also, this dissertation suggests these approaches will improve patient management by identifying mutation specific risk factors for patients with KCNQ1 mutations.

La fibrillation auriculaire (FA) est la forme d’arythmie la plus fréquente et représente environ un tiers des hospitalisations attribuables aux troubles du rythme cardiaque. Les mécanismes d’initiation et de maintenance de la FA sont complexes et multiples. Parmi ceux-ci, une contribution du système nerveux autonome a été identifiée mais son rôle exact demeure mal compris. Ce travail cible l’étude de la modulation induite par l’acétylcholine (ACh) sur l’initiation et le maintien de la FA, en utilisant un modèle de tissu bidimensionnel. La propagation de l’influx électrique sur ce tissu est décrite par une équation réaction-diffusion non-linéaire résolue sur un maillage rectangulaire avec une méthode de différences finies, et la cinétique d'ACh suit une évolution temporelle prédéfinie qui correspond à l’activation du système parasympathique. Plus de 4400 simulations ont été réalisées sur la base de 4 épisodes d’arythmies, 5 tailles différentes de région modulée par l’ACh, 10 concentrations d’ACh et 22 constantes de temps de libération et de dégradation d’ACh. La complexité de la dynamique des réentrées est décrite en fonction de la constante de temps qui représente le taux de variation d’ACh. Les résultats obtenus suggèrent que la stimulation vagale peut mener soit à une dynamique plus complexe des réentrées soit à l’arrêt de la FA en fonction des quatre paramètres étudiés. Ils démontrent qu’une décharge vagale rapide, représentée par des constantes de temps faibles combinées à une quantité suffisamment grande d’ACh, a une forte probabilité de briser la réentrée primaire provoquant une activité fibrillatoire. Cette activité est caractérisée par la création de plusieurs ondelettes à partir d’un rotor primaire sous l’effet de l’hétérogénéité du gradient de repolarisation causé par l’activité autonomique. / Atrial fibrillation (AF) is the most frequent arrhythmia and accounts for about one-third of hospitalizations for cardiac rhythm disturbances. The mechanisms of initiation and maintenance of atrial fibrillation are complex and multifaceted. Among them, a contribution of the autonomic nervous system has been identified but its exact role remains poorly understood. This work targets the study of the effect of autonomic modulation induced by acetylcholine (ACh) on the initiation and maintenance of AF, using a two-dimensional tissue model. Electrical impulse propagation in the tissue was described by as a non-linear reaction-diffusion equation solved on a rectangular mesh with finite difference methods, and ACh kinetics followed a predefined time evolution corresponding to parasympathetic activation. More than 4400 simulations were performed based on 4 fibrillatory initial conditions, 5 sizes of ACh patch, 10 ACh concentrations and 22 time constants representing ACh release and degradation speed. Our results suggest that vagal stimulation can sustain or terminate AF depending on the 4 parameters studied. Results demonstrate that rapid vagal discharge, represented by low time constants combined with sufficient quantities of ACh, has a high probability of breaking the primary reentry and causing fibrillatory activity. This activity is characterized by the generation of several wavelets from a primary rotor under the heterogeneity of repolarization gradient due to autonomic modulation.

Atrial fibrillation (AF) is the most common arrhythmia seen in clinical practice. In cardiac surgery, one-third of the patients experience episodes of AF during the first postoperative days (postoperative AF), and patients with preoperative AF (concomitant AF) can be offered ablation procedures in conjunction with surgery, in order to restore ordinary sinus rhythm (SR). The aim of this work was to study the relation between postoperative AF and inflammation; the long-term consequences of postoperative AF on mortality and late arrhythmia; and atrial function after concomitant surgical ablation for AF. In 524 open-heart surgery patients, C-reactive protein (CRP) serum concentrations were measured before and on the third day after surgery. There was no correlation between levels of CRP and the development of postoperative AF. All 1,419 patients with no history of AF, undergoing primary aortocoronary bypass surgery (CABG) in the years 1997–2000 were followed up after 8.0 years. The mortality rate was 191 deaths/1,000 patients (19.1%) in patients with no AF and 140 deaths/419 patients (33.4%) in patients with postoperative AF. Postoperative AF was an age-independent risk factor for late mortality, with a hazard ratio (HR) of 1.56 (95% CI 1.23–1.98). Postoperative AF patients had a more than doubled risk of death due to cerebral ischaemia, myocardial infarction, sudden death, and heart failure compared with patients without AF. All 571 consecutive patients undergoing primary CABG during the years 1999–2000 were followed-up after 6 years. Questionnaires were obtained from 91.6% of surviving patients and an electrocardiogram (ECG) from 88.3% of all patients. In postoperative AF patients, 14.1% had AF at follow-up, compared with 2.8% of patients with no AF at surgery (p<.001). An episode of postoperative AF was found to be an independent risk factor for development of late AF, with an adjusted risk ratio (RR) of 3.11 (95% CI 1.41–6.87). Epicardial microwave ablation was performed in 20 open-heart surgery patients with concomitant AF. Transthoracic echocardiography was performed preoperatively and at 6 months postoperatively. At 12 months postoperatively 14/19 patients (74%) were in SR with no anti-arrhythmic drugs. All patients in SR had preserved left and right atrial filling waves (A-waves) and Tissue velocity echocardiography (TVE) showed preserved atrial wall velocities and atrial strain. In conclusion, postoperative AF is an independent risk factor for late mortality and later development of AF. There is no correlation between the inflammatory marker CRP and postoperative AF. Epicardial microwave ablation of concomitant AF results in SR in the majority of patients and seems to preserve atrial mechanical function.

Background The prevalence and incidence of stroke are known to increase with age, which, combined with demographic change, means that very old patients with stroke are a growing patient group. Risk factors for incident stroke among very old people have not been widely investigated. The impact of depression on mortality in very old people who have had a stroke also remains unclear.  The aim of this thesis was to investigate the risk factors for incident stroke, the epidemiology of stroke and depression, and the consequences of having had a stroke regarding the risk of depression and mortality among very old people. Methods A randomly selected half of 85-, all 90-, and all ≥95-year-olds in certain municipalities in Västerbotten County, Sweden, and Pohjanmaa County, Finland were targeted in a population-based cohort study from 2000-2012. The 65-, 70-, 75-, and 80-year-olds in all the rural and random samples from the urban municipalities in the same counties were furthermore targeted in a survey in 2010. In the cohort study patients were assessed in their homes, by means of the 15-item Geriatric Depression Scale (GDS-15) and other assessment scales, as well as blood pressure measurements, several physical tests, and a review of medical diagnoses appearing in the medical charts. Incident stroke data were collected from medical charts guided by hospital registry records, cause of death records, and reassessments after 5 years. Depression was defined as a GDS-15 score ≥5. A clinical definition of all depressive disorders, based on assessment scale scores and review of medical charts was also used. A specialist in geriatric medicine evaluated the diagnoses. The survey included yes/no questions about stroke and depression status, and the 4-item Geriatric Depression Scale. Associations with mortality and incident stroke were tested using Cox proportional-hazard models.  Results In the ≥85-year-olds examined in 2005-2007 (n=601), the stroke prevalence was 21.5%, the prevalence of all depressive disorders was 37.8% and stroke was independently associated with depressive disorders (odds ratio 1.644, p=0.038). The prevalence of depression according to GDS-15 scores was 43.2% in people with stroke compared with 25.0% in people without stroke (p=0.001). However, in ≥85-year-olds examined in Sweden from 2000-2012 (n=955), from all past data collections in the study, depression was not independently associated with incident stroke.  In ≥65-year-olds who responded to a survey in 2010 (n=6098), the stroke prevalence rose with age from 4.7% among the 65- to 11.6% among the 80-year-olds (p<0.001). The prevalence of depression rose from 11.0% among the 65- to 18.1% among the 80-year-olds (p<0.001). In the group with stroke, depression was independently associated with dependence in personal activities of daily living and having a life crisis the preceding year, while in the non-stroke group, depression was independently associated with several additional demographic, social and health factors. In ≥85-year-olds examined in 2005-2007 with valid GDS-15 tests (n=452), having had a stroke was associated with increased 5-year mortality [hazard ratio (HR) 1.53, 95% confidence interval (CI) 1.15-2.03]. Having had a stroke and depression was associated with increased 5-year mortality compared with having only stroke (HR 1.90, 95% CI 1.15-3.13), having only depression (HR 1.59, 95% CI 1.03-2.45), and compared with having neither stroke nor depression (HR 2.50, 95% CI 1.69-3.69). Having only stroke without a depression did not increase mortality compared with having neither stroke nor depression. In ≥85-year-olds examined in Sweden from 2000-2012 (n=955), from all past data collections in the study, the stroke incidence was 33.8/1000 person-years during a mean follow-up period of about three years. In a comprehensive multivariate model, atrial fibrillation (HR 1.85, 95% CI 1.07–3.19) and higher systolic blood pressure (SBP; HR 1.19, 95% CI 1.08–1.30 per 10-mmHg increase) were associated with incident stroke overall. In additional multivariate models, diastolic blood pressure (DBP) ≥90 mmHg (HR 2.45, 95% CI 1.47–4.08) and SBP ≥160 mmHg (v. <140 mmHg; HR 2.80, 95% CI 1.53–5.14) were associated with incident stroke. Conclusion The prevalence of both stroke and depression increased with age, and rates were especially high among very old people. Having had a stroke was independently associated with a higher prevalence of depression among very old people, however, depression was not independently associated with a higher incidence of stroke. Having had a stroke was associated with increased all-cause mortality among very old people, but only among those who were also depressed. High SBP (≥160 mmHg), DBP (≥90 mmHg) and atrial fibrillation were the only consistent independent risk factors for incident stroke among very old people. / I västvärlden inklusive Sverige så ökar gruppen av människor som uppnår åldern 80 år eller äldre. Människorna som uppnår denna mycket höga ålder har en hög förekomst av kardiovaskulära riskfaktorer, har ofta flera samtidiga sjukdomar och ofta funktionsnedsättningar. Medicinska behandlingsåtgärder är ofta mindre effektiva och förknippade med biverkningar i åldersgruppen. Stroke är en sjukdom som beror på skada av hjärnvävnad till följd av minskad blodtillhörsel till delar av hjärnan. Det är känt att såväl förekomsten av och insjuknandet i stroke ökar med stigande ålder. Den som drabbas av stroke löper risk att få en bestående funktionsnedsättning och att dö i förtid. En vanlig komplikation efter att ha drabbats av stroke är nedstämdhet eller depression. Vetenskapliga studier om stroke har tidigare negligerat mycket gamla människor, vilket i takt med den pågående demografiska utvecklingen framstått som allt mer orimligt. Det är ej helt klarlagt vilka riskfaktorer som leder till att insjukna med stroke i mycket hög ålder. Överdödligheten förknippad med att drabbas av depression efter stroke är också oklar i åldersgruppen. Det är också oklart vad som skiljer depression efter stroke från depression bland den övriga befolkningen av åldrade människor. Den populations-baserade kohortstudien GErontologisk Regional DAtabas (GERDA) inleddes år 2000 för att kartlägga faktorer förknippade med gott åldrande bland mycket gamla människor. Hälften av 85-åringarna, alla 90-åringar och alla ≥95-åringar i utvalda kommuner i Västerbotten erbjöds att delta i studien. Därefter har återbesök hos tidigare deltagare i sina nya åldersgrupper och rekrytering av nya deltagare genomförts vart femte år. Studien utvidgades med utvalda kommuner i Österbotten, Finland vid den första femårsuppföljningen. Datainsamlingen i studien bestod av demografiska frågor, skattningsskalor, blodtrycksmätning och kognitiva test genomförda vid ett hembesök i deltagarens hem, samt genomgång av journalhandlingar. År 2010 skickades även en enkät ut till 65-, 70-, 75- och 80-åringar i alla kommuner i Västerbotten och Österbotten. Enkäten innehöll frågor om demografi, hälsa, sjukdomar och intressen. Bland deltagarna i kohortstudien bestämdes förekomsten av tidigare stroke baserat på genomgång av journaluppgifter och uppgifter från hembesöken. Förekomsten av depression bestämdes baserat på poängsättning från en validerad skattningsskala för depression, samt baserat på en sammanvägning av journaluppgifter och skattningsskalor. En specialist i geriatrik fattade det slutliga beslutet om diagnoser. Insjuknande i stroke bestämdes baserat på journalgenomgång av individer med stroke-relaterade diagnoskoder i sjukhusregistret, i dödsorsaksregistret eller uppgift om stroke vid femårsuppföljningen i studien. Bland deltagarna i enkätstudien bestämdes förekomsten av tidigare stroke baserat på självrapportering, och förekomsten av depression bestämdes baserat på en sammanvägning av självrapportering och en skattningsskala för depression.  Förekomsten av stroke i enkätstudien steg med ålder, från 4.7% bland 65-åringar till 11.6% bland 80-åringar. Förekomsten av stroke var omkring 20% bland ≥85-åringar, med minimal variation mellan 85-, 90- och ≥95-åringar. Förekomsten av depression var högre bland dem med stroke jämfört med de övriga deltagarna, både gällande den sammavägda diagnosen och baserat endast på poängsättning. Stroke och sömnproblem var oberoende associerade med depression. Bland ≥65-åringar i enkätstudien var funktionsnedsättning och genomgången livskris associerade med depression hos dem med en tidigare stroke. Bland deltagare utan stroke var ett antal ytterligare externa faktorer, inklusive subjektiv upplevelse av dålig ekonomi och att inte ha någon att anförtro sig till, associerade med depression. Både stroke och depression var associerade med ökad dödlighet bland ≥85-åringar. De med stroke utan depression hade en dödlighet i linje med normalbefolkningen utan stroke eller depression. Förekomsten av samtidig stroke och depression var associerad med högre dödlighet än normalbefolkningen, jämfört med dem med enbart stroke eller enbart depression. Högt systoliskt blodtryck (≥160 mmHg), högt diastoliskt blodtryck (≥90 mmHg) och förmaksflimmer var oberoende riskfaktorer för att insjukna i stroke bland ≥85-åringarna. Sambandet mellan blodtryck och strokerisk försvagades ej hos människor med kognitiv eller funktionell nedsättning. Tidigare stroke, hjärtsvikt, kognitiv nedsättning, näringsbrist, depressiva symtom och låg gånghastighet var också associerade med att insjukna i stroke, men ej oberoende av varandra. Sammanfattningsvis så stiger förekomsten av stroke med åldern och är särskilt hög bland mycket gamla människor. Depression är betydligt vanligare hos mycket gamla människor med stroke, även justerat för störningsfaktorer. Depression är främst associerat med funktions-nedsättning hos människor med stroke, men med ett större antal externa faktorer hos människor utan stroke. Mycket gamla människor med stroke har särskilt hög dödlighet om de samtidigt är deprimerade, men en dödlighet i linje med normalbefolkningen om de inte är deprimerade. Högt systoliskt och diastoliskt blodtryck samt förmaksflimmer är viktiga och behandlingsbara orsaker till att drabbas av stroke i mycket hög ålder.

La fibrillation auriculaire (FA) est la forme d’arythmie la plus fréquente et représente environ un tiers des hospitalisations attribuables aux troubles du rythme cardiaque. Les mécanismes d’initiation et de maintenance de la FA sont complexes et multiples. Parmi ceux-ci, une contribution du système nerveux autonome a été identifiée mais son rôle exact demeure mal compris. Ce travail cible l’étude de la modulation induite par l’acétylcholine (ACh) sur l’initiation et le maintien de la FA, en utilisant un modèle de tissu bidimensionnel. La propagation de l’influx électrique sur ce tissu est décrite par une équation réaction-diffusion non-linéaire résolue sur un maillage rectangulaire avec une méthode de différences finies, et la cinétique d'ACh suit une évolution temporelle prédéfinie qui correspond à l’activation du système parasympathique. Plus de 4400 simulations ont été réalisées sur la base de 4 épisodes d’arythmies, 5 tailles différentes de région modulée par l’ACh, 10 concentrations d’ACh et 22 constantes de temps de libération et de dégradation d’ACh. La complexité de la dynamique des réentrées est décrite en fonction de la constante de temps qui représente le taux de variation d’ACh. Les résultats obtenus suggèrent que la stimulation vagale peut mener soit à une dynamique plus complexe des réentrées soit à l’arrêt de la FA en fonction des quatre paramètres étudiés. Ils démontrent qu’une décharge vagale rapide, représentée par des constantes de temps faibles combinées à une quantité suffisamment grande d’ACh, a une forte probabilité de briser la réentrée primaire provoquant une activité fibrillatoire. Cette activité est caractérisée par la création de plusieurs ondelettes à partir d’un rotor primaire sous l’effet de l’hétérogénéité du gradient de repolarisation causé par l’activité autonomique. / Atrial fibrillation (AF) is the most frequent arrhythmia and accounts for about one-third of hospitalizations for cardiac rhythm disturbances. The mechanisms of initiation and maintenance of atrial fibrillation are complex and multifaceted. Among them, a contribution of the autonomic nervous system has been identified but its exact role remains poorly understood. This work targets the study of the effect of autonomic modulation induced by acetylcholine (ACh) on the initiation and maintenance of AF, using a two-dimensional tissue model. Electrical impulse propagation in the tissue was described by as a non-linear reaction-diffusion equation solved on a rectangular mesh with finite difference methods, and ACh kinetics followed a predefined time evolution corresponding to parasympathetic activation. More than 4400 simulations were performed based on 4 fibrillatory initial conditions, 5 sizes of ACh patch, 10 ACh concentrations and 22 time constants representing ACh release and degradation speed. Our results suggest that vagal stimulation can sustain or terminate AF depending on the 4 parameters studied. Results demonstrate that rapid vagal discharge, represented by low time constants combined with sufficient quantities of ACh, has a high probability of breaking the primary reentry and causing fibrillatory activity. This activity is characterized by the generation of several wavelets from a primary rotor under the heterogeneity of repolarization gradient due to autonomic modulation.

Objectif: Déterminer si l’efficacité de l’amiodarone pour le maintien du rythme sinusal varie selon la fonction systolique ventriculaire gauche. Contexte: Malgré un profil de sécurité établi en insuffisance cardiaque, nous ignorons si l’efficacité de l’amiodarone et son impact sur différentes issues cardiovasculaires sont modulés par la fonction ventriculaire gauche. Méthode: Nous avons effectué une analyse combinée de 3307 patients (âgés de 68,0±0,9 ans ; 31,1% de femmes) recrutés dans les études AFFIRM et AF-CHF qui ont été randomisés au contrôle du rythme par l’amiodarone (N=1107) ou au contrôle de la fréquence cardiaque (N=2200). Résultats: Chez les patients sous amiodarone, la survie sans fibrillation auriculaire était de 84% et de 45% à 1 et 5 ans respectivement, sans égard à la fraction d’éjection ventriculaire gauche (P=0,8754, ajusté). De façon similaire, la proportion moyenne ajustée de temps en fibrillation auriculaire (15,0±1,8%) n’a pas été influencée par la fraction d’éjection (P=0,6094). Durant le suivi, 1963 patients (59,4%) ont requis au moins une hospitalisation, incluant 1401 (42,6%) patients hospitalisés pour cause cardiovasculaire. Les taux ajustés d’hospitalisation pour toutes causes et pour cause cardiovasculaire étaient similaires entre les patients sous amiodarone et ceux dans le groupe de contrôle de la fréquence dans l’ensemble de la population ainsi que dans les sous-groupes de patients avec et sans dysfonction ventriculaire gauche sévère. De façon similaire, les taux ajustés de mortalité globale et cardiovasculaire étaient similaires entre chez les patients sous amiodarone et ceux traités par le contrôle de la fréquence dans l’ensemble de la population ainsi que dans les sous-groupes de patients avec et sans dysfonction ventriculaire gauche sévère. Conclusions: L’efficacité de l’amiodarone pour le maintien du rythme sinusal n’est pas influencée par la fonction ventriculaire gauche. Le contrôle du rythme avec l’amiodarone s’associe à des taux de mortalité et d’hospitalisation comparables au contrôle de la fréquence à la fois chez les patients avec et sans dysfonction ventriculaire gauche sévère. / Objectives: To determine whether amiodarone’s efficacy in maintaining sinus rhythm varies according to left ventricular systolic function. Background: Despite amiodarone’s established safety profile in heart failure, it is unknown whether its impact on cardiovascular outcomes is modulated by ventricular function. Methods: We conducted a pooled analysis of 3307 patients (age 68.0±0.9 years; 31.1% female) enrolled in AFFIRM and AF-CHF trials who were randomized to rhythm control with amiodarone (N=1107) or rate control (N=2200). Results: In amiodarone-treated patients, freedom from recurrent atrial fibrillation was 84% and 45% at 1 and 5 years, respectively, with no differences according to left ventricular function (adjusted P=0.8754). Similarly, the adjusted mean proportion of time in atrial fibrillation (15.0±1.8%) did not vary according to ventricular function (P=0.6094). During follow-up, 1963 (59.4%) patients required at least one hospitalization, with 1401 (42.6%) patients hospitalized for a cardiovascular reason. Adjusted all-cause and cardiovascular hospitalization rates were similar with amiodarone versus rate control in the overall population and in subgroups of patients with and without severe left ventricular dysfunction. Similarly adjusted all-cause and cardiovascular mortality rates were similar with amiodarone versus rate control, overall and in subgroups of patients with and without severe left ventricular dysfunction. Conclusions: Amiodarone’s efficacy in maintaining sinus rhythm and reducing the burden of atrial fibrillation is similar in patients with and without left ventricular dysfunction. Rhythm control with amiodarone was associated with similar mortality and hospitalisation rates when compared to rate control in patients with and without severe left ventricular dysfunction.